Cognitive improvement in schizophrenia trials rarely detaches from symptom scores, so the prespecified secondary endpoint in MapLight Therapeutics’ Phase 2 ZEPHYR trial deserves close attention: ML-007C-MA produced a cognitive effect size of 0.51 (p=0.041) in participants with baseline cognitive impairment, and that signal showed no correlation with the concurrent PANSS improvement, suggesting the two effects are running on separate tracks rather than one driving the other.
The ZEPHYR trial met its primary endpoint: the 210/3 mg twice-daily dose of betovumeline co-formulated with fesoterodine delivered a statistically significant 4.5-point PANSS total score improvement over placebo at Week 5, with an effect size of 0.37 in the mITT population (p=0.015). Among completers, the effect size rose to 0.50 and the mean separation widened to 6.0 points (p=0.002), driven by greater improvement in the treatment arm rather than placebo drift. Secondary endpoints held up: CGI-S effect size 0.48 (p=0.002), PANSS Positive Marder Factor effect size 0.39 (p=0.012). The tolerability picture was comparably clean. No serious or drug-related severe adverse events occurred in either active arm. GI discontinuations were just 2.0% at the BID dose. No titration failures, no metabolic signals, no extrapyramidal symptoms, and no urinary retention flags despite the anticholinergic co-formulation. That matters because ML-007C-MA enters a field where Cobenfy (xanomeline-trospium), approved by the FDA in September 2024, already established the muscarinic cholinergic mechanism in schizophrenia but carries its own tolerability constraints that MapLight is explicitly trying to improve on with fesoterodine co-formulation and a one-dose titration requiring no fasting.
The regulatory setup is worth examining carefully. MapLight designed ZEPHYR to be registration-sized, and it plans an End-of-Phase 2 meeting with the FDA before running a second registrational trial. That sequencing matters: the FDA has been moving away from its long-standing de facto two-pivotal-trial requirement, signaling openness to one adequate and well-controlled study supplemented by confirmatory evidence. Whether ZEPHYR alone could anchor a filing or whether a replication trial is required will be the central question coming out of that agency meeting. The once-daily 330/6 mg dose missed the primary endpoint, though it did show separation on CGI-S, PANSS Positive Marder Factor, and Readiness for Discharge. MapLight says further analysis will determine its path forward, but the BID dose is clearly carrying the program now.
The single number to watch from here is what the FDA says about the sufficiency of ZEPHYR as a standalone pivotal study. If the agency accepts the trial design as registration-adequate, MapLight’s second trial becomes confirmatory rather than pivotal, which changes both the timeline and the risk profile of this program materially.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment
The FDA Measures All Schizophrenia Symptoms at the Same Clock. A Six-Trial IPD Analysis Just Proved That’s Wrong.
2 months ago[…] the scene: a principal investigator at a Phase 3 schizophrenia site reviews the Week 6 PANSS assessment for a patient who started a novel antipsychotic four weeks […]
Comments are closed.